Targeting EGFR in Triple Negative Breast Cancer

J Cancer. 2011;2:324-8. doi: 10.7150/jca.2.324. Epub 2011 May 28.

Abstract

Our preliminary data show that erlotinib inhibits Triple-negative breast cancer (TNBC) in a xenograft model. However, inhibition of metastasis by erlotinib is accompanied by nonspecific effects because erlotinib can inhibit other kinases; thus, more direct targets that regulate TNBC metastasis need to be identified to improve its therapeutic efficacy.

Keywords: EGFR; erlotinib; metastasis; triple negative breast cancer; tyrosine kinase inhibitor.